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Levosimendan emerged in the 1990s as a first-in-class inotrope and vasodilator that 
enhanced cardiac contractility by sensitizing the contractile response to cardiac troponin 
C and caused vasodilatation by opening potassium-dependent ATP channels on 
vascular smooth muscle cells. Since its clinical debut in 2000 it has established itself as 
valuable resource in the management of acute decompensated heart failure and is one 
of very few successful medical innovations of its kind in that field in recent decades. Its 
pharmacology is notable for delivering inotropy without an increase in myocardial 
oxygen consumption and for an array of secondary (‘pleiotropic’) effects that include an 
anti-ischemic effect, pre-conditioning and post-conditioning and cardioprotective effects 
and anti-oxidative effects.  
Proceeding from those properties it has been proposed that in addition to its use in 
various scenarios of low cardiac output levosimendan may be beneficial in other 
conditions associated with acutely decompensated heart failure, including right 
ventricular failure, subarachnoid hemorrhage, and cardiogenic shock with multi-organ 
dysfunction. The potential of levosimendan for kidney protection in situations of cardio-
renal syndrome has been identified. Additional lines of investigation include the use of 
levosimendan for perioperative hemodynamic support, its administration as repeated 
intermittent infusions to sustain patients with advanced heart failure and its application 
in a range of critical care settings. 
Levosimendan has also provided a template and a starting point for the development of 
a new generation of cardio-active drugs and is currently being evaluated in advanced 
clinical trials for the management of amyotrophic lateral sclerosis. 
The molecule levosimendan 
The use of inotropes for correcting hemodynamic dysfunction in patients with congestive 
heart failure (HF) has been described over many decades [1]. In the 1990s, a new 
compound with both inotropic and vasodilatory properties was discovered and developed:  
the calcium sensitizer and potassium-channel opener levosimendan. This discovery was 
made possible by new insights into the molecular structure of the protein known to trigger 
and sustain contraction in cardiomyocytes slow twitch muscle fibers, i.e. the cardiac 
isoform of troponin C [2–4], and the main mechanism of action (MoA) of levosimendan 
derives from its selective binding to this particular molecular target [5–11]. In parallel, other 
effects of levosimendan were characterized in several non-clinical models and its 
potassium-channel-opening effect [12] and direct effects on mitochondria [13, 14] were 
discovered and characterized. Furthermore, inhibition of oxidative stress and apoptosis 
and modulation of autophagy, were suggested to represent one possible mechanisms of 
protection by levosimendan against cardiac, renal and liver injuries [15]. In addition, a 
potential role for levosimendan as nitric oxide synthase activator has been described in 
both endothelial cells and animal models [16, 17]. 
Finally, an active metabolite of levosimendan was identified and its MoA was 
characterized, showing similarities with its parent drug both as inotrope and vasodilator 
[18]. Some years ago, a review authored by many experts in the field collected and 




The pharmacology of levosimendan 
The effects of levosimendan have been studied in various cellular, tissue, organ and 
animal models in vitro, ex vivo and in vivo [20]. Levosimendan was clearly differentiated 
from other inotropes such as enoximone [21] and milrinone [22, 23]: its unique MoA is at 
the origin of an inotropic effect [24] that does not entail an increase in oxygen consumption 
[22, 25-27], and the mechanisms involving the other targets give origin to a vasodilating 
effect [28-30], an anti-ischemic effect [23, 31], preconditioning, post-conditioning and 
cardioprotective effects [12, 32-36], anti-remodeling effects [37], anti-oxidative effects [38, 
39] and positive signals on animal survival [40]. The pharmacology of OR-1896, the active 
metabolite of levosimendan, has also been characterized [41, 42]. Finally, the interactions 
of levosimendan with relevant drugs have been studied and reported [43, 44]. 
 
Clinical settings 
With a range of pleiotropic effects and a consequent multi-faceted pharmacology, 
levosimendan found clinical use in various settings of acute cardiac care. A general review 
of its current utility [45] described its use as hemodynamic support in acutely 
decompensated HF, cardiogenic shock, perioperative settings, critical care settings, 
weaning from respiratory support, weaning from extracorporeal membrane oxygenation 
(ECMO), weaning from inotrope support and advanced heart failure (AdvHF). Indeed, a 
consensus of experts suggested that, in addition to its use in typical scenarios of low 
cardiac output (CO), levosimendan might be expected to exert favorable effects in various 
other conditions associated with acutely decompensated HF (Table 1). Those additional 
clinical scenarios (outlined by Farmakis et al. [46]) included: acute coronary syndrome; 
right ventricular failure; subarachnoid hemorrhage; cardiac surgery, either with preserved 
organ function or complicated by renal dysfunction; hepatic injury; and cardiogenic shock 
with multi-organ dysfunction. In the following sections, we will systematically describe the 
use of levosimendan in those settings. 
 
Acutely decompensated HF 
Acute heart failure (AHF) refers to a rapid decline in cardiac pump function requiring 
urgent medical care. It may arise as a de novo entity in a previously asymptomatic patient 
or as an acute exacerbation of previously diagnosed chronic HF. AHF may be regarded as 
an umbrella term describing a complex clinical syndrome that may include the following 
conditions: worsening or decompensated chronic HF; pulmonary edema; hypertensive 
AHF; cardiogenic shock; HF relating to acute coronary syndromes; and isolated right-sided 
HF [47]. Pharmacological interventions must acknowledge these distinct clinical and 
pathophysiological entities. Intravenous (i.v.) inotropic support may be considered in 
patients with hypotension, hypoperfusion or shock for the purpose of maintaining 
peripheral perfusion by increasing CO and blood pressure [48]. 
 
Most inotropic drugs currently in clinical use may be described as calcium mobilizers that 
promote cardiac contractility by increasing influx of ionic calcium (Ca2+) into 
cardiomyocytes. However, cardiomyocyte Ca2+ loading is associated with enhanced 
myocardial oxygen consumption, increased heart rate and greater risk of arrhythmias 
contributing to higher morbidity and mortality rates [24]. 
 
Levosimendan exemplifies an alternative approach of calcium sensitization, by which 
cardiomyocyte sarcomeres are enabled to contract more powerfully in response to given 
concentrations of ionic calcium. This strategy is attractive because it offers the prospect of 
augmented positive inotropy without changes in Ca2+ homeostasis and the attendant 
clinical complications.  
Pivotal short-term trials of levosimendan include the LIDO and RUSSLAN studies, both of 
which documented improvement in short- and mid-term mortality. Findings from the 
SURVIVE and REVIVE trials were more nuanced but a meta-analysis of all regulatory 
Phase II and III trials has identified a significant reduction in mortality in critically ill patients 
treated with levosimendan, and also in those undergoing cardiac surgery [49]. Inter-study 
population heterogeneity, differences in dosage regimens and the use of concomitant 
vasodilator or diuretic therapy may have contributed to the discrepant findings between the 
various levosimendan trials [50]. 
 
Despite the identification of several other drugs that operate on conceptually similar 
principles [24] levosimendan remains the only drug of this kind to have firmly established 
itself in recent years in the clinical repertoire of treatments for AHF [51]. Proceeding from 
that success, levosimendan’s profile as an inotrope that confers short-term clinical benefits 
without adverse long-term events has been proposed as the benchmark and minimum 
standard for any future inotropic or inodilator drug developed for AHF [52], even as a 
complication of acute coronary syndrome [53].  Of utmost interest in this context are the 
data on the effect of levosimendan on the quality of life of AHF patients [54]. 
 
Perioperative hemodynamic support  
Low cardiac output syndrome (LCOS) in patients undergoing cardiac surgery is a serious 
complication associated with high mortality rates. Preoperative reduced left ventricular 
function is a prominent risk factor for LCOS, so there is logic in exploring the potential for 
perioperative levosimendan-mediated inotropy to try to avert the development of LCOS. 
[55]. (Conventional adrenergic agents confer a potential risk of increased myocardial 
oxygen consumption which, in the setting of LCOS, may result in cardiac ischemia, with 
subsequent damage to hibernating but viable myocardium. By contrast, levosimendan 
provides positive inotropy with a neutral effect on oxygen consumption and its 
preconditioning, cardioprotective and anti-ischemic effects may all be advantageous in this 
situation [56, 57], Meta-analysis of this proposition, reviewed in the context of a pan-
European expert overview [55], has provided indications of improved survival plus a 
reduction in non-fatal adverse outcomes such as postoperative renal failure requiring 
dialysis, with greatest treatment effect observed in those with the greatest reduction in left 
ventricular ejection fraction (LVEF) [58]. That expert review [55] identified patients with 
generally compromised myocardial function (including right ventricular dysfunction) as 
likely candidates for perioperative levosimendan but emphasized the need for adequate 
hemodynamic monitoring to anticipate, prevent or treat vasodilatation-related side effects 
and advised not using bolus doses outside the operating room. The desirability of 
expanded clinical research in this area was also noted [55]. 
 
Later action to address that requirement has included the regulatory double-blind, 
randomized controlled trial LEVO-CTS (NCT02025621), which aimed to assess the effect 
of levosimendan in patients with low preoperative LVEF (EF <35%) undergoing scheduled 
or urgent cardiac surgery [59]. 
The LEVO-CTS study confirmed the experience of earlier, smaller investigations that 
levosimendan is safe and well tolerated in patients undergoing cardiac surgery with 
cardiopulmonary bypass who have low LVEF and are at risk of developing 
postoperative LCOS. Levosimendan decreased the incidence of LCOS and diminished 
the need for catecholamines when used during coronary artery bypass surgery. In the 
context of isolated coronary artery bypass grafting (i.e. with no accompanying valve 
surgery), levosimendan significantly decreased postoperative mortality [60]. 
No comparable data are available for any other inotropes, which have in fact been 
associated with detrimental effects on outcome [61]. A recent further exploration of this 
area has concluded that “Preconditioning with levosimendan, is a cost-effective strategy 
preventing postoperative low cardiac output in patients with moderate-severe left 
ventricular systolic dysfunction undergoing elective coronary artery bypass graft 
surgery.” [62] 
  
In critical care settings 
The potential of levosimendan as a critical care resource rests substantially on its multi-
faceted pharmacology, as already discussed. Applications identified in expert 
commentaries and supported by preliminary findings [63] include:  
 cardiogenic shock; 
 septic shock; 
 weaning from mechanical ventilation or ECMO 
 pulmonary hypertension and right ventricular dysfunction 
 hemodynamic support in patients with diuretic resistance. 
 
In addition, levosimendan is advocated for inotropic support in Takotsubo syndrome when 
the option of extracorporeal life support is unavailable [64]. 
 
The scale of studies needed for statistically robust outcomes analysis may be a challenge 
in critical care (owing to small numbers of eligible patients in very focused sub-settings); or 
the plurality of criteria that have to be permitted to acquire sufficient numbers of patients 
may lead to the inclusion of a broad clinical spectrum of participants often subject to 
extensive polypharmacy and other interventions, all of which may obscure any further 
effect of the studied intervention. Smaller studies (perhaps conducted at single centers 
and with closely defined eligibility criteria) may be more effective for revealing positive drug 
effects, but the influence of their results is likely to be limited. Effective responses to this 
dilemma may have to include revisions of trial designs for critical care [63]. 
 
Effects on renal function 
Renal dysfunction is often encountered in HF and in other situations where cardiac 
function is compromised (e.g. cardiac surgery or sepsis). This combination of morbidities, 
sometimes characterized as ‘cardio-renal syndrome’, is a complex pathophysiological 
interplay in which cardiac dysfunction may adversely affect renal function or vice versa. 
Renal dysfunction in the context of HF has been strongly linked with poor prognosis in 
various major clinical trials in HF [65]. 
 
Levosimendan’s action in opening adenosine triphosphate-sensitive potassium channels in 
vascular smooth muscle may be a pertinent consideration in the context of renal 
dysfunction in HF. This action has been linked to organ-preserving effects. In conjunction 
with levosimendan’s effects as a systemic inodilator, this action may mitigate the 
processes of renal dysfunction through several pathways. Systemic contributions to the 
renal-protective effect may include central venous and pulmonary artery wedge pressures, 
thereby alleviating renal vein back-pressure. In addition, levosimendan induces a 
predominant afferent (preglomerular) renal arteriolar vasodilatation, with accompanying 
increases in both renal blood flow (RBF) and glomerular filtration rate (GFR). Thus, there 
are indications that, in patients with HF and impaired renal function, levosimendan may 
exert renal-protective effects via both an increase in CO and a specific renal vasodilatory 
influence [65]. (It should be noted that levosimendan causes balanced increases in GFR 
and renal oxygen delivery. This may be significant because an isolated increase in GFR 
might endanger the oxygenation of the renal medulla, which is sensitive to ischemia [66].) 
 
Results from several recent detailed pathophysiology studies in patients with HF have 
supported the view that levosimendan exerts distinctive and theoretically advantageous 
effects on various aspects of renal hemodynamics, perfusion and function [66]; in 
particular, while both levosimendan and dobutamine have broadly comparable effects on 
systemic hemodynamics and RBF, only levosimendan augments GFR [66]. It must be 
conceded, however, that evidence for a robust clinically favorable impact on renal function 
in HF is inconsistent: the largest levosimendan HF study (REVIVE I and II) yielded no 
significant indications of such an effect. The signals from cardiac surgery studies are also 
inconclusive. Further randomized controlled trials are therefore needed to explore this 
aspect of levosimendan. HF patients who might derive particular benefit from 
levosimendan therapy include: (a) those with HF of ischemic origins; (b) those with well-
sustained systemic blood pressure (systolic blood pressure >100 mmHg) and; (c) those 
being treated with beta-blockers [66].  
 
Repeated infusion in advanced HF 
The later stages of HF are characterized by declining physical capacity, often punctuated 
(and exacerbated) by acute decompensations that require hospitalization. Patients’ 
symptoms become unresponsive or refractory to maximally tolerated doses of the 
conventional medical repertoire for HF, making it progressively more difficult to maintain 
functional capacity and quality of life [67]. At this stage, however, and in contradistinction 
to end-stage or terminal HF, some reversal of the deterioration in cardiac function and/or 
symptoms can still be achieved with intensive interventions. In the face of a continuing 
undersupply of donor hearts for transplantation, options for the management of these 
patients additional to all usual medications include inotropic support. Goals of therapy at 
this juncture include the preservation of major organ function in order to optimize patients’ 
prospects for transplantation or implantation of a ventricular-assist device. Repetitive 
levosimendan therapy may potentially also contribute to a reduction in the need for 
emergency transplantations, although this possibility has not yet been formally examined 
[68]. 
 
Levosimendan, administered as intermittent i.v. infusions, appears to offer preservation, or 
some improvement in, functional capacity and quality of life in advanced HF, with no 
adverse impact on life expectancy. A meta-analysis of data from 319 patients in six trials 
indicated that intermittent use of levosimendan was associated with a significant reduction 
in the number of re-hospitalizations at 3 months (16% vs. 35%, risk ratio 0.40, 95% 
confidence interval 0.27–0.59, p<0.001) [69]. That analysis identified methodological 
limitations in existing studies, however, and its authors emphasized the need for large, 
high-quality, randomized controlled trials to provide confirmation of their finding [70]. 
Consideration of the potential of levosimendan in advanced HF by a panel of international 
experts has highlighted the fact that reliance on symptoms as an objective endpoint in HF 
trials can be unreliable as a metric of intervention success [70]. Inter alia, reliance on a 
composite endpoint may encounter practical obstacles of duration of follow-up and the 
number of patients required to assure statistical power. Instead, therefore, it is proposed 
that a study (or studies) might be conducted using a hierarchical endpoint comprising 
death as a first-tier outcome, with HF-related re-hospitalization and change(s) in natriuretic 
peptides as lower-tier outcomes [70].  This concept is now being pursued in the LEODOR 
trial (NCT03437226; www.leodortrial.com) [71].  
 
Criteria for the identification of advanced HF patients for intermittent i.v. levosimendan 
therapy have been proposed [68]. These comprise:  
 Severe systolic dysfunction (LVEF ≤35%) 
and/or  
 New York Heart Association class IIIb–IV status and/or Interagency Registry for 
Mechanically Assisted Circulatory Support (INTERMACS) levels 4–6 
and/or  
 Repeated hospitalization or emergency department visits (≥2 in the past year) 
 All of the above despite optimal treatment for HF. 
 
When used for intermittent i.v. therapy, it is recommended that levosimendan is 
administered at doses of 0.05–0.2 μg/kg/min for 6–24 h, every 2–4 weeks [68]. Flexibility is 
emphasized, with a suggestion that treatment may be started at a low dose then increased 
stepwise during the infusion period, subject to tolerability, hemodynamic stability and 
broader safety considerations. Use of an initial bolus dose of levosimendan is not 
recommended and hypokalemia and hypovolemia should be avoided before and during 
treatment [68]. Intermittent levosimendan therapy may be conducted on an outpatient 
basis provided the relevant safety dispositions are made. 
 
Intermittent i.v. levosimendan may also have a role in the management of patients with 
irreversible end-stage HF but has not been formally evaluated for this purpose. In this 
setting, the goals of therapy differ importantly from those for advanced HF, with emphasis 
moving towards meeting patients’ existential priorities. The well-being of patients and the 




Various analyses indicate that levosimendan may represent a rational and efficient use of 
resources due to its effects on length of hospitalization and re-hospitalization rate. 
 
In an early example of this, Lucioni et al. [72] conducted an evaluation of levosimendan 
versus dobutamine for the treatment of AHF in Italy. Drawing on data from 300 patients 
treated for AHF at a single center in Rome, and with patients followed up for a year, they 
concluded that the incremental cost of treatment with levosimendan was in effect 
cancelled by the incremental savings, with the greater part of those savings accruing from 
a reduction in the average length of stay (LOS), with a further contribution from a lower re-
hospitalization rate. In that cost analysis, therefore, levosimendan appeared to be a 
competitive alternative to dobutamine from the hospital perspective, even when all non-
monetary health gains were excluded from consideration.  
 
In a separate investigation, Mardiguian et al. [73] used a two-part Markov model to 
conduct a cost-benefit comparison (from a hospital perspective) of levosimendan and 
dobutamine in the perioperative treatment of patients undergoing cardiac surgery who 
required inotropic support. Cost-benefits were evaluated in terms of costs and bed stays in 
the German healthcare system using 2014 drug prices and other relevant published 
information, with a 3% annual discount rate. Key clinical and cost inputs included LOS, 
mortality, medication and adverse events. 
 
Over a 1-year time horizon (the base-case analysis), fewer adverse events and shorter 
hospital LOS meant that the use of levosimendan was associated with cost savings of 
€4787 per patient compared with dobutamine [73]. 
 
A broader perspective on this issue is offered by the work of Nieminen and colleagues, 
who explored the cost-benefit economics of levosimendan therapy for patients hospitalized 
with AHF in seven European countries representing different economic profiles [74]. 
Drawing on data from Finland, Germany, Greece, Italy, Israel, Spain and Sweden, and 
also on extant national data on the costs of medications and on the hospitalization cost per 
day, it was concluded that the use of levosimendan in this scenario yields a net saving to 
hospitals arising from reduction in LOS. The saving was mostly modest in size (<€100) but 
was demonstrated for all the countries considered, ranging from €0.50 in Germany to 
€354.64 in Sweden [74]. Recently, a pharmaco-economic analysis was performed on the 
advanced HF patients enrolled in the LION-HEART study, which showed that intermittent 
ambulatory treatment with levosimendan generated savings for the Spanish national 
health system [75]. 
 
Expert opinions on use and posology 
The vasodilating aspects of levosimendan’s pharmacological profile are relevant to the 
drug's application in low-output states such as AHF. Effects that may be anticipated in 
AHF include improvements in hemodynamics and tissue perfusion and relief of the 
symptoms of congestion and fatigue [76, 77]. To the extent that the goals of therapy in 
advanced HF include hemodynamic stabilization, preservation of functional capacity and 
mitigation of symptoms, similar benefit may be expected from levosimendan in this 
situation. Moreover, use of levosimendan in repeated intermittent cycles does not appear 
to be associated with an increase in mortality, contrary to experiences with conventional 
inotropes [76]. 
 
As a general principle, the use of inotropes, when judged appropriate, should be restricted 
to the lowest dose and the shortest possible period [48]. Within that general prescription, 
experienced expert opinion asserts that levosimendan should ordinarily be administered 
without a loading bolus (to mitigate any risk of hypotension). Continuous infusion for up to 
24 h may be commenced at infusion rates of 0.05–0.1 μg/kg/min, although some 
practitioners initiate therapy at a rate of 0.2 μg/kg/min for the first 60 min (in order to reach 
the desired therapeutic effect more rapidly) before reducing the dose to 0.1 μg/kg/min. The 
levosimendan infusion rate should be closely monitored and individualized according to 
tolerability and hemodynamic response [78]. 
 
Various lines of evidence suggest that, for patients in cardiogenic shock after cardiac 
surgery who require inotrope support for weaning from temporary extracorporeal life 
support, levosimendan may be preferable to milrinone and that it may be superior to 
dobutamine in terms of short-term survival [48]. These preliminary signals are, however, in 
need of confirmation in good-quality clinical trials.  
 
Levosimendan can exert profound vasodilatory effects and so should be administered with 
caution in patients with low blood pressure. Hypovolemia should be avoided before and 
during levosimendan treatment, which possibly should include adjustment of dosage for 
any i.v. diuretics. Attention should also be paid to maintaining serum potassium levels ≥4.0 
mmol/L during levosimendan infusion, in order to avert hypokalemia [77].  
 
Research in other settings: a future for levosimendan 
Levosimendan is currently being evaluated for possible therapeutic benefits in several 
non-clinical models and in >30 regulatory or investigator-initiated clinical trials. We will try 
to describe in this section the main hypotheses and the available data. 
  
Lines of research currently being pursued include the use of levosimendan in pulmonary 
hypertension and respiratory muscle dysfunction, especially in the context of amyotrophic 
lateral sclerosis (ALS; motor neuron disease) [79]. Trials are also in progress to investigate 
the effects of i.v. levosimendan on cellular metabolic alterations in patients with septic 
shock (NCT02963454), on prognosis in acute respiratory distress syndrome 
(NCT04020003) and on quality of life in patients with pulmonary hypertension and HF with 
preserved EF (NCT03541603). 
 
At the preclinical stage, investigations are ongoing into the potential of levosimendan for 
stroke prevention [80] and protection of hepatocytes from liver ischemia/reperfusion injury 
[81]. 
 
In addition to these direct lines of new research with levosimendan, the drug has provided 
structure–activity information that creates a base for the development of candidate agents 
such as ORM-3819, which promotes cardiac contractility through Ca2+ sensitization in 
combination with selective phosphodiesterase-III inhibition [82-84]. 
 
The discovery and development of novel cardio- and vasoactive drugs for the treatment of 
acute hemodynamic derangements has been characterized by repeated disappointments 
in recent decades and new additions to the therapeutic palette would be more than 
welcome [85-87]. Work proceeding from the structure–activity relations identified during 
the development of levosimendan provides one starting point for such activities. 
 
Conclusions 
Levosimendan emerged from research into new possibilities for inotropic therapy for HF 
during the 1980 and 1990s. Related lines of enquiry faltered, however, and other novel 
products either failed to emerge from the laboratory or failed the pragmatic tests applied to 
new drug therapies. To a notable extent, therefore, levosimendan is one of the few durable 
innovations of its kind in AHF in several decades [85-87].  
 
This singularity has contributed to levosimendan establishing itself as a prominent addition 
to the medical armamentarium, aided among other things by the greatly expanded use of  
beta-blockers in the management of HF: the availability of a calcium-sensitizing inotrope 
that works by energy-neutral mechanisms not dependent on adrenergic pathways is a 
tangible advantage and a quality that differentiates levosimendan from conventional 
inotropes such as dobutamine [88, 89]. Similarly, the ability to administer levosimendan in 
an outpatient setting and its persistence of effect due to the formation of a long-acting 
active metabolite has stimulated new interest in the feasibility of ambulatory medical 
management for patients in the more advanced stages of HF, encouraging hopes that 
frequency of hospital admission may be reduced for these patients and health-related 
quality of life preserved. Levosimendan thus occupies a distinctive place in the medical 
management of AHF and AdvHF, delivering significant relief of HF symptoms and exerting 
a variety of potentially favorable effects on a range of hemodynamic, functional and 
neurohormonal parameters. Proceeding from these experiences, levosimendan is 
assigned specific roles in current expert guidelines for the treatment of AHF (a IIb 
recommendation for patients with peripheral hypoperfusion because of low CO) and in 
AdvHF [90, 91]. 
 
As might be expected for a drug of its distinctive identity and longevity, clinical curiosity 
has led to levosimendan being evaluated for a range of applications outside its original 
central indication [92]. That levosimendan exerts a range of ancillary pharmacologic 
effects possibly relevant to various cardiovascular and critical care situations has 
encouraged these lines of enquiry and sustained interest in the drug during the 20 years 
since it was first approved for clinical use. Further research to clarify the impact of 
levosimendan in these spheres of use may be anticipated and in several cases is already 
underway (see, for example, www.leodortrial.com). Most recently, this innovation-directed 
outlook has seen levosimendan enter advanced clinical trials as a possible therapy for 
respiratory compromise in patients with ALS [79, 93]. 
 
More than 250 clinical trials in the latest 26 years have evaluated levosimendan in 
therapeutic settings, including perioperative and AdvHF, and an array of meta-analyses 
have shown a consistent trend towards efficacy and safety: in particular, the increase in 
mortality often identified with adrenergic inotropes has not been observed with 
levosimendan [49, 87] (Figure 1). 
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Table 1: Commonly encountered concomitant conditions in Acute Heart Failure patients 





Legend to the figures 
 
Figure 1: In the ALARM-HF registry, use of the inodilator levosimendan was linked with 
a notably lower mortality rate than traditional adrenergic inotropes. Graphic rendition 
from data by Mebazaa et al [95].  
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